Please ensure Javascript is enabled for purposes of website accessibility

Thai Fighter Jet Bombs Cambodian Targets as Border Battle Escalates

23 hours ago

California Cannot Require Background Checks to Buy Ammunition, US Appeals Court Rules

1 day ago

Wrestling Legend Hulk Hogan Dies at 71, TMZ Reports

1 day ago

TikTok Will Go Dark in US Without Chinese Approval of Sale Deal, Lutnick Says

1 day ago

Meme Stock Surge Underlines Market Froth, Mostly Centered on Retail Investors

1 day ago

Fresno County Authorities Still Searching for Missing Mother and Infant

1 day ago

California Releases Teacher Data. It Shows Big Rise in Hispanic Teachers

1 day ago

Biting a Bat and 5 Other Wild Moments From Ozzy Osbourne’s Life

1 day ago

Henry Thompson Did Wonders for Fresno Airport, Leaves ‘Incredibly Big Shoes to Fill’

2 days ago
How North America Trade Deal Dealt a Setback to Big Pharma
gvw_ap_news
By Associated Press
Published 6 years ago on
December 19, 2019

Share

A revamped North American trade deal is nearing passage in Congress, giving both the White House and House Democrats cause to claim victory. There is relief, too, for farmers and businesses that wanted clearer rules governing the vast flow of goods among the United States, Canada and Mexico.

“This is one of the first times we’ve actually seen Pharma lose. They have a remarkable track record because they are a huge political force. They spend lots of money on lobbying, on advertising, on campaign contributions. But we held firm, and we won on all counts.” — Rep. Earl Blumenauer, an Oregon Democrat who leads a subcommittee on trade
But the pact left at least one surprising loser: The pharmaceutical industry, a near-invincible lobbying powerhouse in Washington.
To satisfy House Democrats, the Trump administration removed a provision that would have given the makers of ultra-expensive biologic drugs 10 years of protection from less-expensive knockoffs. The Democrats opposed what they called a giveaway to the industry that could have locked in inflated prices by stifling competition. Top biologics include drugs that fight cancer and others that combat immune disorders like rheumatoid arthritis.
“This is one of the first times we’ve actually seen Pharma lose,” said Rep. Earl Blumenauer, an Oregon Democrat who leads a subcommittee on trade. “They have a remarkable track record because they are a huge political force. They spend lots of money on lobbying, on advertising, on campaign contributions. But we held firm, and we won on all counts.”
The removal of the provision dealt a rare setback to pharmaceutical companies and helped illustrate just how potent a political issue sky-high drug prices have become. It was a reminder, too, that Trump had repeatedly pledged to work to lower drug prices.

Ultra-Costly Injected Drugs Made From Living Cells

Last week, drug manufacturers absorbed another — though likely only a temporary — defeat when House Democrats passed legislation, along party lines, that would authorize Medicare to use its influence in the marketplace to negotiate lower prices from drug companies. The bill is thought to have no chance of passage, though, in the Republican-led Senate.
Yet the revamped U.S.-Mexico Canada Agreement, Trump’s rewrite of the 25-year-old North American Free Trade Act, seems set to clear Congress — without the biologics protection that the drug industry had sought. On Tuesday, the House Ways and Means Committee approved the legal text of the agreement. The full House is expected to approve it Thursday, though the Senate isn’t likely to take it up until January.
“It’s not a mystery,’’ said Rep. Jan Schakowsky, an Illinois Democrat who helped negotiate with the administration onthe trade deal. “If you poll the American people, the cost of pharmaceuticals is a really big deal. It’s at the top of the list.’’
The trade agreement the administration reached last year with Mexico and Canada gave biologics — ultra-costly injected drugs made from living cells — 10 years of protection from cheaper near-copies known as biosimilars. Among the leading biologics are the anti-cancer drugs Rituxan and Humira and Enbrel, which fight immune disorders.
The industry — and the Trump administration — had argued that manufacturers of biologics require years of protection to profit from their drugs before biosimilars should be allowed to cut into sales. Otherwise, they contend, brand-name drug companies and biotech startups that rely on money from venture capital firms would have little incentive to invest in developing new medicines.

Existing U.S. Law Already Gives Makers of Biologics 12 Years’ Protection

“The announcement made today puts politics over patients,” the leading drug industry trade group, PhRMA, said in a statement last week. “Eliminating the biologics provision in the USMCA removes vital protections for innovators while doing nothing to help U.S. patients afford their medicines or access future treatments and cures.’’

“The announcement made today puts politics over patients. Eliminating the biologics provision in the USMCA removes vital protections for innovators while doing nothing to help U.S. patients afford their medicines or access future treatments and cures.’’ — leading drug industry trade group, PhRMA
The industry also rejected the notion that the biologics provision would keep drug prices high and hurt consumers: Existing U.S. law, they noted, already gives makers of biologics 12 years’ protection, more than the 10 years in USMCA. But the provision the Democrats succeeded in removing would have forced Mexico to expand biologics’ monopoly from five years and Canada from eight — potentially hurting U.S. consumers who seek lower drug prices in those countries.
What’s more, Democrats argued, if Congress had expanded the biologics’ monopoly in USMCA, it would have prevented lawmakers from ever scaling back that monopoly to, say, the seven years that the Obama administration had once proposed.
“We would have been locked in,’’ Schakowsky said.
For Big Pharma, the setback marked a sharp turnabout. Just four years ago, the drug industry had helped scuttle an Obama administration trade deal with 11 Pacific Rim countries, arguing that its eight years of protection for biologics weren’t sufficient. Now, the latest U.S. trade deal contains no biologics protections at all.
 

Drug Makers Began Raising Prices of Existing Drugs Several Times a Year

Back in 2006, the industry had scored a major victory when it helped push legislation through Congress that added prescription drug coverage for Medicare recipients — but barred the government from negotiating lower prices. That restriction opened a “Pandora’s box” that paved the way for unsustainable price hikes, said Steve Brozak, an analyst at WBB Securities.
Drug makers began raising prices of existing drugs several times a year, sometimes totaling more than 20% or more annually. They also started launching biologic drugs, a rapidly growing share of new drugs, with list prices topping six figures a year. In May, U.S. regulators approved a one-time gene therapy, Zolgensma, with an eye-popping price of $2.1 million per patient.
A backlash has been growing, especially after news reports and congressional hearings exposed stories of patients rationing medicine and even dying because they couldn’t afford insulin or other drugs.
Drugmakers have “been on defense more than we’ve ever seen,” said David Certner, legal counsel for AARP.
Last year, Certner noted, Congress dealt the industry two losses: First, by increasing the discounts that drug makers must give to seniors with high drug costs who have landed in a Medicare coverage gap — and then by rejecting industry efforts months later to reverse that change.

Trump Has Long Promised to Address Drug Prices

And in January, the industry lost perhaps its biggest champion in Congress when Sen. Orrin Hatch, R-Utah, retired.
Trump has long promised to address drug prices. And on Wednesday the administration moved ahead with a plan to allow Americans to safely and legally gain access to lower-priced medicines from abroad. So far, most of Trump’s drug-price initiatives have gone nowhere. And his trade team had negotiated biologics protections into the USMCA.
Facing public anger, Democratic resistance and the fact that Canada and Mexico had no reason to support the protections for biologics, the administration yielded. When it reached a deal with House Democrats on USMCA last week, the biologics provision was out.
“Clearly, getting rid of the biologic provision was a step backwards,” U.S. Trade Representative Robert Lighthizer said in an interview Tuesday with the Fox Business Network. “And that was a compromise. You know, there are consequences of the Democrats’ control of the House. And that was necessary. And I’m sorry about that.”
Jeffrey Francer, general counsel for the Association for Accessible Medicines, which represents generic and biosimilar drug companies, put it another way: “The president decided not to fall on his sword for Big Pharma.’’

DON'T MISS

What Are Fresno Real Estate Experts Predicting for 2025 and Beyond?

DON'T MISS

First California EV Mandates Hit Automakers This Year. Most Are Not Even Close

DON'T MISS

Trump: Strong Dollar Sounds Good but ‘You Make a Hell of a Lot More’ With a Weaker One

DON'T MISS

US Appeals Court Rejects Challenge to Washington Laws Concerning Transgender Minors

DON'T MISS

Tesla to Roll out Bay Area Robotaxis With Safety Drivers, Report Says

DON'T MISS

Trump Says He Has Not Considered Clemency for Ghislaine Maxwell

DON'T MISS

Fresno Police Arrest Felon in Connection With Drive-by Shooting

DON'T MISS

US Clears Way for $8 Billion Paramount-Skydance Merger

DON'T MISS

Thailand and Cambodia Exchange Heavy Artillery Fire as Border Battle Expands

DON'T MISS

Trump Says US May Not Have a Negotiated Trade Deal With Canada

DON'T MISS

Netanyahu, Trump Appear to Abandon Gaza Ceasefire Negotiations With Hamas

DON'T MISS

Valley Crime Stoppers’ Most Wanted Person of the Day: Julian Jay Haymon

UP NEXT

Trump Says US May Not Have a Negotiated Trade Deal With Canada

UP NEXT

Trump Says There Is a 50-50 Chance of Trade Deal With EU

UP NEXT

Amid Epstein Furor, Ghislaine Maxwell Seeks Relief From US Supreme Court

UP NEXT

US Justice Department Official Meets Epstein Associate Maxwell

UP NEXT

Lara Trump Skips North Carolina US Senate Race, Clears Way for Cooper Versus Whatley

UP NEXT

Michael Whatley, RNC Chair, to Run for Senate in North Carolina

UP NEXT

Video-Sharing App Vine Is Returning ‘in AI Form’, Musk Says

UP NEXT

CBS News Taps Tanya Simon as New Boss of ’60 Minutes’ After Trump Lawsuit

UP NEXT

Justice Department to Assess Claims of ‘Alleged Weaponization’ of US Intelligence Community

UP NEXT

White House Not Denying That Trump’s Name Appears in Epstein Files, Official Says

Trump Says He Has Not Considered Clemency for Ghislaine Maxwell

52 minutes ago

Fresno Police Arrest Felon in Connection With Drive-by Shooting

60 minutes ago

US Clears Way for $8 Billion Paramount-Skydance Merger

1 hour ago

Thailand and Cambodia Exchange Heavy Artillery Fire as Border Battle Expands

1 hour ago

Trump Says US May Not Have a Negotiated Trade Deal With Canada

2 hours ago

Netanyahu, Trump Appear to Abandon Gaza Ceasefire Negotiations With Hamas

2 hours ago

Valley Crime Stoppers’ Most Wanted Person of the Day: Julian Jay Haymon

2 hours ago

Trump Says There Is a 50-50 Chance of Trade Deal With EU

2 hours ago

Amid Epstein Furor, Ghislaine Maxwell Seeks Relief From US Supreme Court

2 hours ago

Tater Is One Hot Potato When It Comes to Adoptable Kittens

2 hours ago

Trump: Strong Dollar Sounds Good but ‘You Make a Hell of a Lot More’ With a Weaker One

WASHINGTON — President Donald Trump said on Friday he liked a strong dollar but “you make a hell of a lot more money” with a wea...

16 minutes ago

President Donald Trump speaks after disembarking Marine One, as he departs for Scotland, at Joint Base Andrews, Maryland, U.S., July 25, 2025. (Reuters/Evelyn Hockstein)
16 minutes ago

Trump: Strong Dollar Sounds Good but ‘You Make a Hell of a Lot More’ With a Weaker One

Family members and advocates gather inside the Lutheran Church of the Reformation near the U.S. Supreme Court after justices supported a Republican-backed ban in Tennessee on gender-affirming medical care for transgender minors, during a rally in Washington, D.C., U.S., June 18, 2025. (Reuters File)
28 minutes ago

US Appeals Court Rejects Challenge to Washington Laws Concerning Transgender Minors

A Tesla robotaxi drives on the street along South Congress Avenue in Austin, Texas, U.S., June 22, 2025. (Reuters File)
39 minutes ago

Tesla to Roll out Bay Area Robotaxis With Safety Drivers, Report Says

Jeffrey Epstein associate Ghislaine Maxwell stands at the podium to address Judge Alison Nathan during her sentencing in a courtroom sketch in New York City, U.S. June 28, 2022. (Reuters File)
52 minutes ago

Trump Says He Has Not Considered Clemency for Ghislaine Maxwell

60 minutes ago

Fresno Police Arrest Felon in Connection With Drive-by Shooting

Paramount Global logo is seen in this illustration taken December 17, 2024. REUTERS/Dado Ruvic/Illustration
1 hour ago

US Clears Way for $8 Billion Paramount-Skydance Merger

A Thailand's mobile artillery unit fires towards Cambodia's side after Thailand and Cambodia exchanged heavy artillery on Friday as their worst fighting in more than a decade stretched for a second day, in Surin, Thailand, July 25, 2025. REUTERS/Athit Perawongmetha
1 hour ago

Thailand and Cambodia Exchange Heavy Artillery Fire as Border Battle Expands

A 3D-printed miniature model of U.S. President Donald Trump, the Canada flag and the word "Tariffs" are seen in this illustration taken July 23, 2025. (Reuters/Dado Ruvic/Illustration)
2 hours ago

Trump Says US May Not Have a Negotiated Trade Deal With Canada

Help continue the work that gets you the news that matters most.

Search

Send this to a friend